India’s pandemic hell could be purgatory 23 Apr 2021 There is hope rising immunity and the country’s massive vaccine industry will bring a rapid end to the misery brought about by a terrifying second wave of contagion. New Delhi has little room to act if the economy follows hospitals into a state of collapse. Cracks are visible.
The Exchange: Fewer bankers, more engineers needed 20 Apr 2021 That’s one of Jacques Attali’s many prescriptions to enhance the economy of life. The former EBRD boss and French presidential adviser also discusses Big Tech breakups, Europe’s lagging vaccination efforts, Macron’s political prospects and his plan to close the elite ENA.
Thruppence: Lessons from a few border crossings 19 Apr 2021 Lockdowns are easing in some countries as vaccination efforts pick up. But professionals eager to get back on the road still need to become quick studies on the fine print of pandemic-era international travel rules. Three itinerant Breakingviews columnists share their notes.
Viewsroom: Cross-border travel hassles, Alibaba 15 Apr 2021 For businesspeople eager to get back on the road, three lucky Breakingviews editors share their experiences of hopping across the Atlantic, traveling to India and navigating Europe’s arbitrary rules. Asia columnists discuss how Beijing has come down hard on Jack Ma’s tech empire.
Capital Calls: Delta Air Lines, L’Oreal 15 Apr 2021 Concise views on global finance: The U.S. air carrier says it was cash-flow positive in March, signaling the beginning of the end of the pandemic; the French cosmetics group has too much cash, which could be useful for dealmaking.
The Exchange: ECB President Christine Lagarde 14 Apr 2021 What role does the central bank play in combatting climate change? How will it confront the emergence of digital currencies? What if the U.S. economy charges ahead while Europe languishes? Lagarde takes on these questions and more in an exclusive discussion with Breakingviews.
Virgin Active gives landlords a post-virus sweat 14 Apr 2021 The pandemic-hit gym group founded by Richard Branson wants lower rents. It’s using a new restructuring tool to force the issue with support from other creditors. Faced with a wave of copycats, bruised property owners’ only option is to be more selective about future tenants.
Vaccine fiasco casts long shadow over Oxford IPO 12 Apr 2021 A university spinoff behind the AstraZeneca jab is listing for a mooted $700 mln. Vaccitech’s technology might combat diseases from cancer to hepatitis. Yet lingering doubts over efficacy and side-effects on Covid-19 patients are a risky legacy in a highly competitive sector.
How to play the post-Covid return to getting it on 12 Apr 2021 Rich-country birth rates fell in 2020 amid economic uncertainty, reduced social life, postponed nuptials and fertility treatments. The patter of tiny feet will return as lockdowns end and economies bounce. Diaper producers and formula makers like P&G and Reckitt stand to benefit.
DiaSorin wisely hedges against Covid-19 test slump 12 Apr 2021 The Italian diagnostic group which has benefited from pandemic demand is buying smaller U.S. peer Luminex for $1.8 bln. Thanks to hefty cost savings the deal makes financial sense. With vaccinations accelerating, it’s a good time to seek more enduring sources of revenue.
Capital Calls: Netflix, GameStop 9 Apr 2021 Concise views on global finance in the Covid-19 era: The video-streaming service sprays webs of money to secure movies; GameStop’s “Chewy of Gaming” strategy.
Gaming weakness puts Ubisoft on M&A last life 9 Apr 2021 Shares in the “Assassin’s Creed” publisher have languished since a failed takeover by Vivendi in 2018. Despite a pandemic boost, CEO Yves Guillemot’s $10 bln group suffers from dour profitability. That leaves him open to attack by rivals like Activision Blizzard or Tencent.
Covid-testing IPO is bet on long hypochondria 7 Apr 2021 German diagnostic tester Synlab is planning to float with a mooted $7 bln valuation. A receding pandemic may mean its 38% revenue growth in 2020 isn’t repeated. But the price reflects that, and consumers may well continue to obsess about other aspects of their health.
Vax surplus will be Uncle Sam’s hardest soft power 6 Apr 2021 America’s supply of Covid-19 jabs is burgeoning. The nation will soon have a surplus. The U.S. says it won’t trade these for political favors. But giving the glut away will still pay strategic and economic dividends. Vaccines are the opposite of a Trump-style zero-sum game.
Rosier IMF forecasts are riddled with inequalities 6 Apr 2021 The international lender upgraded its global growth forecasts for this year and next. But there is a gulf between haves and have-nots, across countries and within them. Some of the sound advice it is doling out to mitigate the problem may be hard for governments to implement.
Air France-KLM’s latest rescue tests marriage bond 6 Apr 2021 The European carrier is swapping a loan from the French state for hybrid equity and raising 1 bln euros from investors. The capital rejig should help it stay aloft if the recovery is delayed. But Paris’ increased stake will strain its already tricky relationship with the Dutch.
Cox: Europe really needs to get its shot together 1 Apr 2021 From Rome to Paris and beyond governments are imposing further travel and other restrictions, many for reasons that look more petty, political and punitive than sanitary. That’s energy better spent on the best way to exit the health and economic crisis: vaccinating people.
Deliveroo’s IPO cash hunger leaves sour aftertaste 30 Mar 2021 The UK food delivery firm’s offering values it at 7.6 bln pounds, the bottom of the target price range. Despite its rapid growth and big ambitions, investors face post-pandemic uncertainty. Boss Will Shu’s order for 1 bln pounds of fresh cash suggests profitability is a way off.
AstraZeneca could use a shot of under-promising 29 Mar 2021 The pharma group got caught in a spat between states over vaccine supplies, partly due to PR gaffes and overhasty pledges. A refresh of the board and chairman would be one way to overcome an episode that has hurt credibility and hampered rollout of a good product millions want.
Vaccine halo merits the effort for American pharma 29 Mar 2021 The success of Pfizer, J&J and Moderna in developing Covid-19 jabs and scaling up production has buffed their reputations. The immediate financial gain – about $4 bln of profit for Pfizer this year – may pale beside the benefit from having regulators and lawmakers on their side.